Role of Tie2, CD14, angiopoietin as angiogenetic markers in hepatocellular carcinoma complicating hepatitis C virus infection in Egyptian patients

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Hepatobiliary Cancers
Cancer Treatment in Patients with Comorbidities
Translational Research
Presenter El-zahraa Meghezel
Citation Annals of Oncology (2018) 29 (suppl_9): ix46-ix66. 10.1093/annonc/mdy432
Authors E.M. Meghezel1, H. Abdelhfez Ahmed2, A.A. Askar3, E.E.N. Hassan4, A. Elyamany5
  • 1Tropical Medicine And Gastroenterology, Sohag University., 002 - sohag/EG
  • 2Clinical Pathology, Sohag University., 002 - sohag/EG
  • 3Internal Medicine, Sohag University., 002 - sohag/EG
  • 4Emad Eldin Nabil Hassan, Sohag University., 002 - sohag/EG
  • 5Medical Oncology, South Egypt Cancer Institute SECI Assiut University, 7151 - Assiut/EG



Hepatocellular carcinoma (HCC) is the second most common worldwide cancer, but biomarkers for early detection remain challengeable. TIE2-expressing monocyte (TEMs) cells display pro-tumoral activities. The aim of the study was to examine the expression of TEM which is defined as CD14+ TIE2+ and angiopoietin-2 in hepatocellular carcinoma and its potential use as a diagnostic tumor marker in HCC patients with HCV induced liver cirrhosis.


This study was conducted on 112 Patients admitted to our tropical medicine department and 38 controls divided into two groups: Group I comprised 78 patients with HCC; group II comprised 34 patients with cirrhosis. Both groups were compared with 38 (age and sex-matched) healthy persons as group III.


level of TEMs & serum Ang-2 were significantly higher in HCC patients compared with liver cirrhotic patients and healthy controls. Sensitivity & specificity in diagnosis of HCC respectively were CD14 (89.7%, 83.3%), TIE 2 (76.9%, 83.3%). Ang-2 (76.9%, 66.7%).


These results suggest that TEMs & Ang-2 increase in patients with HCC supporting the idea that TEMs & Ang-2 can be used as a diagnostic marker for HCC, especially among the high-risk group of patients.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Sohag University Ethical Comittee.


Has not received any funding.


All authors have declared no conflicts of interest.